CARA logo

Cara Therapeutics (CARA) Company Overview

Profile

Full Name:

Cara Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

January 31, 2014

Indexes:

Not included

Website:

http://www.caratherapeutics.com

Description:

Cara Therapeutics, Inc. is a biopharmaceutical company conducting clinical trials. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut. The company specializes in the development and commercialization of chemical compounds designed to relieve pain and itching by targeting kappa opioid receptors. The company is developing a class of candidate drugs targeting the peripheral nervous system of the body. The company is engaged in activities related to the discovery and development of therapeutic agents for the treatment of serious conditions, including pain and itching. The company's candidate drugs include I.V. CR845 for acute pain management; I.V. CR845 for uremic itching; oral CR845 for acute and chronic pain relief, and CR701 for neuropathic and inflammatory pain management.

Key Details

Price

$4.39

Market Cap

$20.07 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$20.97 M(-49.92% YoY)

Annual EPS

-$26.28(-37.74% YoY)

PE Ratio

-

Annual ROE

-109.80%

Annual Debt To Equity

0.00

Beta

0.90

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Mar 4, 2025

Recent annual earnings:

Mar 4, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Dec 31, 2024

Analyst ratings

Recent major analysts updates

Jun 13, 24 Needham
Hold
Jun 13, 24 HC Wainwright & Co.
Neutral
Jun 13, 24 Canaccord Genuity
Hold
May 23, 24 Needham
Buy
May 15, 24 HC Wainwright & Co.
Buy
May 14, 24 Needham
Buy
Apr 10, 24 Needham
Buy
Mar 6, 24 Canaccord Genuity
Buy
Mar 5, 24 Needham
Buy
Jan 22, 24 Needham
Buy

Screeners with CARA included

Growing Shares Outstanding
US stocks
Stocks recommended to hold
Best performing stocks last 3 months
Stocks below analysts price target
Healthcare sector
All stocks
Biotechnology industry
Small cap stocks
NASDAQ earnings calendar

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$4.39
CARA price is $4.39

Price All-time High

$350.28
CARA price is currently -98.75% below its historical high of $350.28

Price Analysts Target

$12.00
CARA price is currently -63.41% lower than the consensus analysts' forecast

Price Today Change

-2.43%
CARA price is down -2.43% today

Price YTD Change

-28.26%
CARA price is down -28.26% since January 1st

Price 3-Year Change

-96.58%
CARA price is down -96.58% over the past 3 years

Market cap

Market Cap

$20.07 M
CARA market capitalization is $20.07 million

Market Cap 3-Year Change

-96.49%
CARA market capitalization is down -96.49% over the past 3 years

Market Cap All-time High

$1.46 B
CARA market capitalization is currently -98.63% below its historical high of $1.46 billion

Market Cap Sector Rank

25.35%
CARA market capitalization is higher than 25.35% of companies in Healthcare sector

Technical

Beta

0.90
CARA beta is 0.90

200-day SMA

$4.46
CARA price is currently -1.58% below its 200-day simple moving average

14-day RSI

38.17
CARA 14-day relative strength index is 38.17

30-day Relative Volume

0.97
CARA 30-day relative volume is 0.97

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$20.97 M
CARA annual revenue is $20.97 million

Annual Revenue Analysts Estimate

$4.80 M
CARA annual revenue is currently +336.83% higher than the consensus analysts' forecast

Annual Revenue 1-Year Change

-49.92%
CARA annual revenue is down -49.92% year-on-year

Annual Revenue Sector Rank

37.82%
CARA annual revenue is higher than 37.82% of companies in Healthcare sector

Profit

Annual Gross Profit

$14.79 M
CARA annual gross profit is $14.79 million

Annual Gross Margin

70.56%
CARA annual gross profit margin is 70.56%

Annual Operating Profit

-$121.50 M
CARA annual operating income is -$121.50 million

Annual Operating Margin

-579.43%
CARA annual operating profit margin is -579.43%

Annual Net Income

-$118.51 M
CARA annual net profit is -$118.51 million

Annual Net Margin

-565.21%
CARA annual net profit margin is -565.21%

EPS

Annual EPS

-$26.28
CARA annual earnings per share is -$26.28

Annual EPS Analysts Estimate

-
CARA annual earnings per share consensus analysts' forecast is unknown

Annual EPS 1-Year Change

-37.74%
CARA annual earnings per share is down -37.74% year-on-year

Annual EPS Sector Rank

8.97%
CARA annual earnings per share is higher than 8.97% of companies in Healthcare sector

ROA & ROE

Annual ROA

-76.94%
CARA annual return on assets is -76.94%

Annual ROE

-109.80%
CARA annual return on equity is -109.80%

EBIT & EBITDA

Annual EBIT

-$117.91 M
CARA annual earnings before interest & taxes is -$117.91 million

Annual EBITDA

-$117.65 M
CARA annual EBITDA is -$117.65 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
CARA price to earnings ratio value is unknown

PE Ratio Sector Rank

-
CARA price to earnings ratio is unknown

PB Ratio

PB Ratio

28.39
CARA price to book ratio is 28.39

PB Ratio Sector Rank

97.28%
CARA price to book ratio is higher than 97.28% of companies in Healthcare sector

PS Ratio

PS Ratio

2.31
CARA price to sales ratio is 2.31

PS Ratio Sector Rank

43.12%
CARA price to sales ratio is higher than 43.12% of companies in Healthcare sector

Enterprise value

Enterprise Value

-$13.57 M
CARA enterprise value is -$13.57 million

Enterprise Value Sector Rank

4.18%
CARA enterprise value is higher than 4.18% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

0.15
CARA EV/EBITDA is 0.15

EV/EBITDA Sector Rank

68.67%
CARA EV/EBITDA is higher than 68.67% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

4.54
CARA annual current ratio is 4.54

Annual Quick Ratio

4.43
CARA annual quick ratio is 4.43

Leverage

Annual Debt To Equity

0.00
CARA annual debt to equity ratio is 0.00

Annual Interest Coverage Ratio

-195.21
CARA annual interest coverage ratio is -195.21

Risk & Stability

Piotroski F-Score

-
CARA piotroski f-score value is unknown

Altman Z-Score

-9.50
CARA altman z-score is -9.50

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$125.84 M
CARA annual total assets is $125.84 million

Annual Non Current Assets

$9.69 M
CARA annual long term assets is $9.69 million

Annual Current Assets

$116.16 M
CARA annual total current assets is $116.16 million

Annual Cash & Cash Equivalents

$51.77 M
CARA annual cash & cash equivalents is $51.77 million

Equity

Annual Book Value

$57.09 M
CARA annual book value is $57.09 million

Annual Working Capital

$90.57 M
CARA annual working capital is $90.57 million

Liabilities

Annual Total Liabilities

$68.76 M
CARA annual total liabilities is $68.76 million

Annual Total Long Term Liabilities

$43.17 M
CARA annual total long term liabilities is $43.17 million

Annual Current Liabilities

$25.59 M
CARA annual total current liabilities is $25.59 million

Annual Accounts Payable

$11.58 M
CARA annual accounts payable is $11.58 million

Debt

Annual Total Debt

$6.09 M
CARA annual total debt is $6.09 million

Annual Total Debt 1-Year Change

+217.41%
CARA annual total debt is up +217.41% year-on-year

Annual Long Term Debt

$6.09 M
CARA annual long term debt is $6.09 million

Annual Short Term Debt

$0.00
CARA annual short term debt is $0.00

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$142.46 M
CARA annual total expenses is $142.46 million

Annual Operating Expenses

$136.29 M
CARA annual total operating expenses is $136.29 million

Annual Cost Of Goods Sold

$6.17 M
CARA annual cost of goods sold is $6.17 million

Annual SGA

$27.65 M
CARA annual SGA is $27.65 million

Annual D&A

$259.00 K
CARA annual depreciation & amortization is $259.00 thousand

Annual Interest Expense

$604.00 K
CARA annual interest expense is $604.00 thousand

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$92.08 M
CARA annual cash flow from operations is -$92.08 million

Annual CFO 1-Year Change

-16.95%
CARA annual cash flow from operations is down -16.95% year-on-year

Annual CFI

$43.46 M
CARA annual cash flow from investing activities is $43.46 million

Annual CFI 1-Year Change

-66.23%
CARA annual cash flow from investing activities is down -66.23% year-on-year

Annual CFF

$38.15 M
CARA annual cash flow from financing activities is $38.15 million

Annual CFF 1-Year Change

+12167.2%
CARA annual cash flow from financing activities is up +12167.2% year-on-year

Free CashFlow

Annual FCF

-$94.45 M
CARA annual free cash flow is -$94.45 million

Annual FCF 1-Year Change

-19.91%
CARA annual free cash flow is down -19.91% year-on-year

CAPEX

Annual CAPEX

$2.38 M
CARA annual capital expenditures is $2.38 million

Annual CAPEX 1-Year Change

+5423.26%
CARA annual capital expenditures is up +5423.26% year-on-year

Institutional Ownership

Similar stocks

TENX logo
Tenax Therapeutics (TENX)
IRIX logo
IRIDEX (IRIX)
JUNS logo
Jupiter Neurosciences (JUNS)
IXHL logo
Incannex Healthcare Limited (IXHL)
LGVN logo
Longeveron (LGVN)
LIAN logo
LianBio (LIAN)
NXTC logo
NextCure (NXTC)
IINN logo
Inspira Technologies Oxy BHN (IINN)
VSee Health (VSEE)

FAQ

  • What is the ticker symbol for Cara Therapeutics?
  • Does Cara Therapeutics pay dividends?
  • What sector is Cara Therapeutics in?
  • What industry is Cara Therapeutics in?
  • What country is Cara Therapeutics based in?
  • When did Cara Therapeutics go public?
  • Is Cara Therapeutics in the S&P 500?
  • Is Cara Therapeutics in the NASDAQ 100?
  • Is Cara Therapeutics in the Dow Jones?
  • When was Cara Therapeutics's last earnings report?
  • When does Cara Therapeutics report earnings?
  • Should I buy Cara Therapeutics stock now?

What is the ticker symbol for Cara Therapeutics?

The ticker symbol for Cara Therapeutics is NASDAQ:CARA

Does Cara Therapeutics pay dividends?

No, Cara Therapeutics does not pay dividends

What sector is Cara Therapeutics in?

Cara Therapeutics is in the Healthcare sector

What industry is Cara Therapeutics in?

Cara Therapeutics is in the Biotechnology industry

What country is Cara Therapeutics based in?

Cara Therapeutics is headquartered in United States

When did Cara Therapeutics go public?

Cara Therapeutics's initial public offering (IPO) was on January 31, 2014

Is Cara Therapeutics in the S&P 500?

No, Cara Therapeutics is not included in the S&P 500 index

Is Cara Therapeutics in the NASDAQ 100?

No, Cara Therapeutics is not included in the NASDAQ 100 index

Is Cara Therapeutics in the Dow Jones?

No, Cara Therapeutics is not included in the Dow Jones index

When was Cara Therapeutics's last earnings report?

Cara Therapeutics's most recent earnings report was on Mar 4, 2025

When does Cara Therapeutics report earnings?

The date for Cara Therapeutics's next earnings report has not been announced yet

Should I buy Cara Therapeutics stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions